Skip to main content
UniHealth

Doctor search

Bita Fakhri, MD

Hematology/Oncology · Stanford

NPI 1568729424

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Community Hospital of the Monterey Peninsula · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fakhri’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A152281 · Current

Licensed to practise in California · since 2017 · expires 2027-04-30 · Iran Medical Centre Aka Iran University of Medical Sciences.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

3 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Community Hospital of the Monterey Peninsula
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.48 (1.22 to 1.74)WorseJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths3.12 (1.69 to 4.56) · 1,095 casesWorseJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths19.24 (14.17 to 24.3) · 1,118 casesWorseJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths9.62 (6.42 to 12.82) · 1,086 casesWorseJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.39BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.27 (0.39 to 2.16) · 1,873 casesNo differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths158.2 (110.65 to 205.75) · 140 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.3 · 74 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.8 · 135 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 184 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.7 · 686 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths16.4 · 1,072 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8 · 328 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.8 · 3,300 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.29 (0.11 to 0.48) · 10,234 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.1 to 0.46) · 10,572 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.25 (1.47 to 5.04) · 2,617 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.37 (1.04 to 3.7) · 2,519 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.21 (0.75 to 3.66) · 744 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.61 (0.06 to 1.17) · 8,715 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths5.2 · 156 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.28No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.799No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.732No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.7 · 152 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.6 · 625 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits6.3 · 193 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-3.2 · 749 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits7 · 1,074 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.5 · 850 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4 (2.7 to 5.8) · 224 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits13.5 (10.4 to 17.4) · 224 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 153 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11.5 · 49 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 144 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits14.2 (10.9 to 18.6) · 711 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (1 to 1.5) · 746 casesNo differentJan 2024 – Dec 2024

What patients said (520 patients answered, 28% of those asked)

Patient survey stars by topic at Community Hospital of the Monterey Peninsula
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information3
Overall hospital rating5
Quietness3
Recommend hospital5
Share of patients giving the best answer at Community Hospital of the Monterey Peninsula
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained62%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge84%
Doctors "always" explained things so they could understand75%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect89%
Patients who gave a rating of "9" or "10" (high)82%
Staff "always" explained new medications79%
Nurses "always" explained things so they could understand79%
Nurses "always" listened carefully77%
Nurses "always" treated them with courtesy and respect89%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital84%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$117,076

Medicare paid this office $117,076 for 307 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)120$33,776$154
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes63$33,211$106
Long return visit (40+ min)89$19,321$119
Initial hospital care with moderate level of medical decision making at least 75 minutes48$8,594$151
Return visit (30+ min)47$6,775$119
See all 9 services
Every Original Medicare service billed
Long return visit (40+ min)120$33,776$154
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes63$33,211$106
Long return visit (40+ min)89$19,321$119
Initial hospital care with moderate level of medical decision making at least 75 minutes48$8,594$151
Return visit (30+ min)47$6,775$119
New patient visit (60+ min)40$6,029$151
Hospital discharge day management, more than 30 minutes40$4,480$104
New patient visit (60+ min)15$2,961$197
Return visit (30+ min)19$1,497$71

Who their Medicare patients are

307 Original Medicare patients in 2024. Average age 76 · Women 39% · Also on Medicaid 13% · Health risk score 2.14. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 67% · Coronary heart disease 33% · Atrial fibrillation 28% · Chronic kidney disease 26% · Diabetes 22% · Heart failure 21% · Cancer 19% · Depression 14% · COPD 12% · Stroke 10% · Dementia 9%.

The office billed $501,351, Medicare allowed $156,201 and paid $117,076; for 940 services of 12 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024307940762.14$501,351$117,076
2023240689752.16$372,153$81,667
2022225578732.49$420,121$47,766
2021172524732.51$420,444$60,928
2020153572722.60$463,195$52,937
2019135437722.47$439,413$40,914
20184456702.18$49,536$6,477

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 5 services

Original Medicare services billed in 2023
Long return visit (40+ min)161$42,030$122
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes46$24,030$107
New patient visit (60+ min)48$7,334$153
Initial hospital care with moderate level of medical decision making at least 75 minutes29$5,128$160
Hospital discharge day management, more than 30 minutes20$2,237$107

2022: 4 services

Original Medicare services billed in 2022
Long return visit (40+ min)155$25,929$112
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$7,224$89
New patient visit (60+ min)19$3,161$166
Biopsy and aspiration of bone marrow sample for diagnosis19$1,031$52

2021: 4 services

Original Medicare services billed in 2021
Long return visit (40+ min)126$46,940$122
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes15$5,171$92
New patient visit (60+ min)33$5,024$152
Return visit (30+ min)16$1,439$90

2020: 4 services

Original Medicare services billed in 2020
Long return visit (40+ min)94$29,770$97
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$7,989$94
Return visit (30+ min)62$6,060$66
New patient visit (60+ min)34$4,991$147

2019: 4 services

Original Medicare services billed in 2019
Long return visit (40+ min)72$17,053$94
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes29$8,462$92
New patient visit (60+ min)47$6,507$138
Return visit (30+ min)45$4,687$70

2018: 2 services

Original Medicare services billed in 2018
New patient visit (60+ min)21$3,129$149
Long return visit (40+ min)21$2,452$98

Medicaid work

$9,794 in 2024

Medicaid paid $9,794 for 175 billed services this clinician did in 2024, up to 15 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES175$9,794
Medicaid work by year
2024175115$9,794
202246313$3,641
202152115$7,877
202013112$1,351
See the largest Medicaid services in earlier years

2022

Largest Medicaid services in 2022
Long return visit (40+ min)17$1,905
COMPREHENSIVE METABOLIC PANEL14$1,243
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count15$493

2021

Largest Medicaid services in 2021
Long return visit (40+ min)52$7,877

2020

Largest Medicaid services in 2020
Long return visit (40+ min)13$1,351

Drugs they prescribed that Part D paid

$1,181,874

Pharmacies billed $1,181,874 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 150) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.

77 generic and 73 brand-name prescriptions · $1,181,874 in drug cost · 23 antibiotic prescriptions to 13 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Jaypirca18$487,039$27,058
Brukinsa21$275,222$13,106
Imbruvica13$199,209$15,324
Calquence11$155,288$14,117
Acyclovir16$230$14
See all 6 drugs
Every Part D drug this clinician prescribed
Jaypirca18$487,039$27,058
Brukinsa21$275,222$13,106
Imbruvica13$199,209$15,324
Calquence11$155,288$14,117
Acyclovir16$230$14
Levofloxacin17$124$7

Year by year

Part D prescribing by year
2024150510% (0)49%$1,181,874
2023126500% (0)54%$1,037,684
2022231620% (0)50%$1,338,053
202150568None34%$2,084,217
2020522763% (14)32%$2,229,843
2019342576% (20)25%$1,007,109
201830None0% (0)None$55,879
20163116NoneNone$1,111
201522023NoneNone$6,235
2014220320% (0)None$9,471
2013298484% (11)None$21,574

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Calquence31$455,384$14,690
Jaypirca13$298,938$22,995
Brukinsa15$227,344$15,156
Levofloxacin11$209$19

2022: 4 drugs

Part D drugs prescribed in 2022
Calquence29$417,143$14,384
Brukinsa19$266,851$14,045
Imbruvica16$247,524$15,470
Acyclovir38$1,048$28

2021: 12 drugs

Part D drugs prescribed in 2021
Imbruvica46$669,665$14,558
Calquence39$526,964$13,512
Brukinsa23$307,086$13,352
Revlimid15$287,427$19,162
Xarelto11$5,708$519
Acyclovir105$1,738$17
Omeprazole19$374$20
Ondansetron20$299$15
Prednisone20$197$10
Entecavir11$156$14
Sulfamethoxazole-Trimethoprim19$97$5
Lorazepam18$65$4

2020: 14 drugs

Part D drugs prescribed in 2020
Imbruvica53$719,450$13,575
Revlimid36$625,562$17,377
Calquence30$448,016$14,934
Venclexta18$221,587$12,310
Atovaquone14$8,892$635
Entecavir11$3,626$330
Acyclovir119$1,846$16
Dapsone13$1,043$80
Valacyclovir12$690$57
Ondansetron15$261$17
Prednisone24$219$9
Dexamethasone12$169$14
Sulfamethoxazole-Trimethoprim27$116$4
Lorazepam11$55$5

2019: 10 drugs

Part D drugs prescribed in 2019
Revlimid32$509,748$15,930
Imbruvica26$327,920$12,612
Atovaquone11$6,246$568
Acyclovir54$848$16
Oxycodone11$389$35
Dexamethasone13$219$17
Ondansetron17$210$12
Prednisone23$154$7
Sulfamethoxazole-Trimethoprim18$57$3
Lorazepam12$38$3

2015: 3 drugs

Part D drugs prescribed in 2015
Amlodipine Besylate32$123$4
Metformin15$76$5
Glipizide12$46$4

2014: 4 drugs

Part D drugs prescribed in 2014
Amlodipine Besylate39$174$4
Gabapentin14$121$9
Hydrochlorothiazide18$62$3
Lisinopril11$50$5

2013: 8 drugs

Part D drugs prescribed in 2013
Metoprolol40$1,755$44
Atorvastatin14$658$47
Torsemide13$335$26
Lisinopril36$259$7
Isosorbide Mononitrate Er11$197$18
Amlodipine Besylate21$148$7
Simvastatin14$90$6
Furosemide18$64$4

Money from drug and device companies

$21,686 in 2025

Industry payments by year
2025522$18,130$21,686
2024342$44,579$48,107
2023847$62,150$65,133
2022713$13,591$14,957
202135$5,225$5,252
2020410$8,238$9,198
2019411$4,850$6,360

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AbbvieVenclexta$14,754
14 payments
  • Consulting · 2025-12-18 · $1,500
  • Meals for Venclexta · 2025-12-06 · $55
  • Meals for Venclexta · 2025-12-06 · $15
  • Meals for Venclexta · 2025-12-05 · $123
  • Meals for Venclexta · 2025-12-05 · $25
  • Consulting for Venclexta · 2025-11-26 · $2,250
  • Consulting for Venclexta · 2025-11-26 · $3,000
  • Consulting for Venclexta · 2025-11-26 · $3,000
  • Travel for Venclexta · 2025-10-07 · $392
  • Travel for Venclexta · 2025-10-06 · $693
  • Travel for Venclexta · 2025-10-06 · $701
  • Consulting for Venclexta · 2025-03-25 · $750
  • Consulting for Venclexta · 2025-02-26 · $750
  • Consulting · 2025-01-30 · $1,500
Genentech USARituxan$3,554
5 payments
  • Travel for Rituxan · 2025-05-30 · $165
  • Travel for Rituxan · 2025-05-30 · $413
  • Consulting for Rituxan · 2025-05-30 · $2,050
  • Meals for Rituxan · 2025-05-30 · $232
  • Travel for Rituxan · 2025-05-30 · $693
AstraZeneca Pharmaceuticals LPCalquence$2,010
1 payment
  • Consulting for Calquence · 2025-05-20 · $2,010
Secura BioCopiktra$1,320
1 payment
  • Paid to speak or teach for Copiktra · 2025-02-13 · $1,320
Janssen BiotechImbruvica$48
1 payment
  • Meals for Imbruvica · 2025-12-05 · $48
See all 22 published payments
Every published payment
AbbvieConsulting · 2025-12-18None$1,500
AbbvieMeals · 2025-12-06Venclexta$55
AbbvieMeals · 2025-12-06Venclexta$15
Janssen BiotechMeals · 2025-12-05Imbruvica$48
AbbvieMeals · 2025-12-05Venclexta$123
AbbvieMeals · 2025-12-05Venclexta$25
AbbvieConsulting · 2025-11-26Venclexta$2,250
AbbvieConsulting · 2025-11-26Venclexta$3,000
AbbvieConsulting · 2025-11-26Venclexta$3,000
AbbvieTravel · 2025-10-07Venclexta$392
AbbvieTravel · 2025-10-06Venclexta$693
AbbvieTravel · 2025-10-06Venclexta$701
Genentech USATravel · 2025-05-30Rituxan$165
Genentech USATravel · 2025-05-30Rituxan$413
Genentech USAConsulting · 2025-05-30Rituxan$2,050
Genentech USAMeals · 2025-05-30Rituxan$232
Genentech USATravel · 2025-05-30Rituxan$693
AstraZeneca Pharmaceuticals LPConsulting · 2025-05-20Calquence$2,010
AbbvieConsulting · 2025-03-25Venclexta$750
AbbvieConsulting · 2025-02-26Venclexta$750
Secura BioPaid to speak or teach · 2025-02-13Copiktra$1,320
AbbvieConsulting · 2025-01-30None$1,500
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $48,107

Payments by company in 2024
Lilly USAJaypirca$23,399
19 payments
  • Paid to speak or teach for Jaypirca · 2024-07-12 · $1,250
  • Paid to speak or teach for Jaypirca · 2024-06-27 · $1,250
  • Travel for Jaypirca · 2024-05-23 · $166
  • Paid to speak or teach for Jaypirca · 2024-05-17 · $2,200
  • Paid to speak or teach for Jaypirca · 2024-05-17 · $2,500
  • Meals for Jaypirca · 2024-05-14 · $110
  • Travel · 2024-05-14 · $771
  • Paid to speak or teach for Jaypirca · 2024-04-03 · $2,500
  • Paid to speak or teach for Jaypirca · 2024-04-03 · $1,575
  • Meals for Jaypirca · 2024-03-29 · $34
  • Paid to speak or teach for Jaypirca · 2024-03-25 · $1,250
  • Paid to speak or teach for Jaypirca · 2024-03-20 · $2,500
  • Paid to speak or teach for Jaypirca · 2024-03-20 · $1,575
  • Meals for Jaypirca · 2024-03-18 · $26
  • Travel · 2024-03-07 · $182
  • Paid to speak or teach for Jaypirca · 2024-02-29 · $2,500
  • Paid to speak or teach for Jaypirca · 2024-02-29 · $1,575
  • Meals for Jaypirca · 2024-02-27 · $30
  • Paid to speak or teach for Jaypirca · 2024-01-26 · $1,406
AbbvieVenclexta$21,486
16 payments
  • Meals for Venclexta · 2024-12-07 · $14
  • Meals for Venclexta · 2024-12-07 · $50
  • Meals for Venclexta · 2024-12-06 · $124
  • Paid to speak or teach for Venclexta · 2024-08-13 · $2,025
  • Paid to speak or teach for Venclexta · 2024-07-30 · $1,350
  • Travel for Venclexta · 2024-07-19 · $390
  • Paid to speak or teach for Venclexta · 2024-07-02 · $3,150
  • Travel for Venclexta · 2024-06-06 · $783
  • Consulting · 2024-06-05 · $4,125
  • Paid to speak or teach for Venclexta · 2024-04-30 · $2,250
  • Consulting · 2024-04-11 · $3,850
  • Paid to speak or teach for Venclexta · 2024-04-09 · $1,350
  • Meals for Venclexta · 2024-04-09 · $125
  • Consulting for Venclexta · 2024-04-04 · $550
  • Meals for Venclexta · 2024-03-21 · $0
  • Paid to speak or teach for Venclexta · 2024-03-12 · $1,350
AstraZeneca Pharmaceuticals LPCalquence$3,222
7 payments
  • Travel for Calquence · 2024-08-07 · $121
  • Consulting for Calquence · 2024-07-22 · $2,498
  • Travel for Calquence · 2024-07-13 · $20
  • Meals for Calquence · 2024-07-13 · $75
  • Travel for Calquence · 2024-07-13 · $449
  • Meals for Calquence · 2024-07-13 · $16
  • Meals for Calquence · 2024-07-13 · $44

2023: $65,133

Payments by company in 2023
Lilly USAJaypirca$29,422
18 payments
  • Paid to speak or teach · 2023-11-17 · $1,875
  • Paid to speak or teach · 2023-11-02 · $1,575
  • Paid to speak or teach · 2023-11-02 · $2,500
  • Paid to speak or teach · 2023-10-27 · $2,200
  • Paid to speak or teach · 2023-10-27 · $2,500
  • Paid to speak or teach · 2023-10-27 · $1,250
  • Travel · 2023-10-19 · $660
  • Paid to speak or teach · 2023-10-10 · $950
  • Consulting · 2023-10-10 · $2,813
  • Paid to speak or teach · 2023-10-10 · $2,500
  • Meals · 2023-10-05 · $122
  • Paid to speak or teach · 2023-09-18 · $2,500
  • Paid to speak or teach · 2023-09-18 · $1,575
  • Meals · 2023-09-13 · $116
  • Paid to speak or teach · 2023-08-14 · $950
  • Paid to speak or teach · 2023-08-14 · $2,500
  • Meals for Jaypirca · 2023-08-09 · $24
  • Paid to speak or teach · 2023-04-19 · $2,813
AbbvieVenclexta$23,091
20 payments
  • Consulting for Venclexta · 2023-11-23 · $6,000
  • Consulting for Venclexta · 2023-11-21 · $2,750
  • Travel for Venclexta · 2023-11-21 · $25
  • Meals for Venclexta · 2023-11-04 · $65
  • Meals for Venclexta · 2023-11-04 · $59
  • Meals for Venclexta · 2023-11-04 · $22
  • Travel for Venclexta · 2023-08-30 · $36
  • Meals for Venclexta · 2023-08-30 · $28
  • Travel for Venclexta · 2023-08-30 · $46
  • Consulting for Venclexta · 2023-08-30 · $3,850
  • Consulting for Venclexta · 2023-08-30 · $1,650
  • Travel for Venclexta · 2023-07-22 · $816
  • Travel for Venclexta · 2023-07-21 · $381
  • Travel for Venclexta · 2023-07-20 · $393
  • Consulting for Venclexta · 2023-06-27 · $550
  • Consulting for Venclexta · 2023-01-19 · $1,650
  • Consulting for Venclexta · 2023-01-10 · $4,400
  • Travel for Venclexta · 2023-01-10 · $70
  • Meals for Venclexta · 2023-01-10 · $25
  • Consulting for Venclexta · 2023-01-04 · $275
Janssen BiotechImbruvica$3,240
2 payments
  • Consulting for Imbruvica · 2023-12-22 · $1,440
  • Consulting for Imbruvica · 2023-06-30 · $1,800
AstraZeneca Pharmaceuticals LPCalquence$2,081
1 payment
  • Consulting for Calquence · 2023-04-05 · $2,081
Genentech USALunsumio$1,932
2 payments
  • Meals for Venclexta · 2023-07-11 · $32
  • Consulting for Lunsumio · 2023-04-18 · $1,900
BeiGene USABrukinsa$1,875
1 payment
  • Consulting for Brukinsa · 2023-02-24 · $1,875
E.R. Squibb & Sons L.L.C.None$1,779
1 payment
  • Consulting · 2023-10-16 · $1,779
Pharmacyclics LLC An AbbVieImbruvica$1,713
2 payments
  • Meals for Imbruvica · 2023-09-15 · $63
  • Consulting for Imbruvica · 2023-07-17 · $1,650

2022: $14,957

Payments by company in 2022
AbbvieVenclexta$5,170
4 payments
  • Travel for Venclexta · 2022-10-19 · $951
  • Travel for Venclexta · 2022-10-19 · $202
  • Travel for Venclexta · 2022-10-19 · $167
  • Consulting for Venclexta · 2022-09-22 · $3,850
Eli Lilly andNone$4,381
2 payments
  • Consulting · 2022-12-21 · $4,375
  • Meals · 2022-08-29 · $6
Genentech USAVenclexta$1,765
1 payment
  • Consulting for Venclexta · 2022-10-11 · $1,765
Janssen Scientific AffairsImbruvica$1,515
1 payment
  • Consulting for Imbruvica · 2022-12-06 · $1,515
E.R. Squibb & Sons L.L.C.None$1,194
2 payments
  • Meals · 2022-12-10 · $8
  • Consulting · 2022-02-09 · $1,186
CSL BehringHizentra$900
2 payments
  • Honoraria for Hizentra · 2022-04-25 · $450
  • Consulting · 2022-02-16 · $450
Pharmacyclics LLC an AbbVieImbruvica$33
1 payment
  • Meals for Imbruvica · 2022-12-12 · $33

2021: $5,252

Payments by company in 2021
CSL BehringHizentra$3,600
3 payments
  • Consulting · 2021-08-06 · $900
  • Consulting for Hizentra · 2021-06-16 · $2,250
  • Consulting for Hizentra · 2021-06-16 · $450
BeiGene USANone$1,625
1 payment
  • Consulting · 2021-11-01 · $1,625
Pharmacyclics LLC An AbbVieImbruvica$27
1 payment
  • Meals for Imbruvica · 2021-05-19 · $27

2020: $9,198

Payments by company in 2020
AstraZeneca Pharmaceuticals LPCalquence$3,735
7 payments
  • Consulting for Calquence · 2020-12-17 · $1,388
  • Consulting for Calquence · 2020-12-17 · $1,388
  • Meals for Calquence · 2020-02-13 · $41
  • Travel for Calquence · 2020-02-13 · $224
  • Travel for Calquence · 2020-02-13 · $189
  • Travel for Calquence · 2020-02-13 · $480
  • Meals for Calquence · 2020-02-13 · $26
AmgenBlincyto$2,400
1 payment
  • Paid to speak or teach for Blincyto · 2020-02-14 · $2,400
EpizymeTazverik$1,813
1 payment
  • Honoraria for Tazverik · 2020-11-11 · $1,813
Adaptive BiotechnologiesClonoseq$1,250
1 payment
  • Consulting for Clonoseq · 2020-12-16 · $1,250

2019: $6,360

Payments by company in 2019
Pharmacyclics LLC An AbbVieImbruvica$3,074
7 payments
  • Consulting for Imbruvica · 2019-07-23 · $1,700
  • Travel for Imbruvica · 2019-05-31 · $397
  • Travel for Imbruvica · 2019-05-31 · $147
  • Meals for Imbruvica · 2019-05-31 · $44
  • Meals for Imbruvica · 2019-05-31 · $38
  • Travel for Imbruvica · 2019-05-30 · $543
  • Travel for Imbruvica · 2019-05-30 · $205
Eli Lilly andNone$1,650
1 payment
  • Consulting · 2019-06-18 · $1,650
Seattle GeneticsAdcetris$1,625
2 payments
  • Meals for Adcetris · 2019-03-15 · $125
  • Paid to speak or teach for Adcetris · 2019-03-15 · $1,500
Genentech USAVenclexta$11
1 payment
  • Meals for Venclexta · 2019-12-17 · $11

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
BeiGene, Ltd. · A Phase 3, Open-Label, Randomized Study of Sonrotoclax (Bgb-11417) Plus Zanubrutinib (Bgb-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia · 2025Their institution$1,458,453
Genmab A/S · A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (Gen3013; Duobody-Cd3 X Cd20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. · 2024Their institution$1,302,382
Genmab A/S · A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (Gen3013; Duobody-Cd3 X Cd20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. · 2025Their institution$935,502
BeiGene, Ltd. · A Phase 3, Open-Label, Randomized Study of Sonrotoclax (Bgb-11417) Plus Zanubrutinib (Bgb-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia · 2024Their institution$666,614
BeOne Medicines Ltd. · A Phase 3, Open-Label, Randomized Study of Sonrotoclax (Bgb-11417) Plus Zanubrutinib (Bgb-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia · 2025Their institution$307,598
ABBVIE INC. · Study To Evaluate Adverse Events Change in Disease Activity and How Oral Abbv-101 Moves Through the Body in Adult Participants With B-Cell Malignancies · 2025Their institution$277,018
Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2021Their institution$262,298
Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2022Their institution$258,366
BeOne Medicines Ltd. · A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-Cd20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2025Their institution$218,865
Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2020Their institution$200,526
ABBVIE INC. · Study To Evaluate Adverse Events Change in Disease Activity and How Oral Abbv-101 Moves Through the Body in Adult Participants With B-Cell Malignancies · 2024Their institution$166,886
Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) · 2024Their institution$149,009
ABBVIE INC. · First-in-Human Study To Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the Btk Degrader, Abbv-101, in Participants With B-Cell Malignancies · 2025Their institution$136,061
Celgene Corporation · An Open-Label, Phase 1/2 Study of Jcar017 in Subje - An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) · 2022Their institution$114,215
BeOne Medicines USA, Inc. · A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-Cd20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2025Their institution$108,304
Celgene Corporation · An Open-Label, Phase 1/2 Study of Jcar017 in Subje · 2021Their institution$81,598
Genmab A/S · A Phase 1b/2, Open-Label Trial To Assess the Safety and Preliminary Efficacy of Epcoritamab (Gen3013; Duobody-Cd3xcd20) in Combination With Other Agents in Subjects With B-Cell Non-Hodgkin Lymphoma. · 2023Their institution$46,178
Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) · 2025Their institution$41,604
Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2019Their institution$2,884
ABBVIE INC. · Multicenter, Evaluator-Blinded, Randomized, Controlled Study of the Safety and Effectiveness of Juvederm Volite Xc Injectable Gel for Improvement in Neck Appearance · 2025Their institution$1,780
Eli Lilly and Company · A Phase 3 Open-Label Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) · 2023This clinician$1,333
Eli Lilly and Company · A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With A Covalent Bruton Tyrosine Kinase Inhibitor · 2024Their institution$1,307
ABBVIE INC. · M23-647 Abbv-101 Ph1 Rr Nhl Fih · 2024Their institution$1,221
Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) · 2024This clinician$900
ABBVIE INC. · First-in-Human Study To Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the Btk Degrader, Abbv-101, in Participants With B-Cell Malignancies · 2024Their institution$672
Genmab A/S · A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (Gen3013; Duobody-Cd3 X Cd20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. · 2023Their institution$206
ABBVIE INC. · First-in-Human Study of the Bcl-2 Inhibitor Abbv-453 in Biomarker-Selected Subjects With Relapsed Or Refractory Multiple Myeloma · 2025Their institution$128

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1568729424
Licence
CA A152281California A152281: Current · expires 2027-04-30
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
Yes
Taxonomy
Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X)
Mailing address
300 Pasteur Dr, Palo Alto, CA, 94304
NPI first listed
2012-04-17
NPI last updated
2024-04-29
NPI record certified
2024-04-29

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 400 Parnassus Ave, San Francisco, CA, 94143